RTP Mobile Logo
The Current and Future Role of Immunotherapies in the Management of Genitourinary Cancers
Released April 2016

Proceedings from a CME symposium held at the 2016 Genitourinary Cancers Symposium. Featuring perspectives from Drs Charles G Drake, David F McDermott, Elizabeth R Plimack, Thomas Powles and Susan F Slovin. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

    OVERVIEW OF ACTIVITY
    The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Although they may be diverse in terms of their biology and current clinical management, genitourinary (GU) cancers — prostate cancer, renal cell carcinoma (RCC), bladder cancer, et cetera — are unified in their potential as fertile ground for immunologic therapy and research and have been at the forefront of both past and current efforts in this regard. Not surprisingly, with the many exciting advances rapidly occurring both within the field of GU tumors and elsewhere, a number of vexing questions and clinical challenges are emerging simultaneously.

    These video proceedings from a CME symposium held during the 2016 Genitourinary Cancers Symposium feature discussions with leading investigators in the management of prostate, renal and bladder cancer regarding actual patient cases and related clinical research findings. By providing information on important immunotherapeutic developments, this activity will assist medical and radiation oncologists, urologists and other healthcare professionals to address existing management uncertainties and determine the current and future roles of immunotherapeutic interventions for patients with common GU cancers.

    LEARNING OBJECTIVES
    • Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various tumor types evade this process to proliferate and grow.
    • Analyze the biologic basis for various immunotherapeutic strategies designed to boost an individual’s immune response to combat cancer.
    • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available systemic therapies for patients with advanced prostate cancer, bladder cancer and RCC.
    • Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational immunotherapies for the treatment of prostate cancer, RCC, bladder cancer and other GU tumors to determine the current and/or potential utility of these agents in clinical practice.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies for metastatic RCC and bladder cancer.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutic agents in order to offer supportive management strategies.
    • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, and counsel appropriately selected patients with GU cancers about trial availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles G Drake, MD, PhD
    Co-Director, Multi-D Prostate Cancer Clinic
    Co-Director, Division of Immunology
    Professor of Oncology, Urology and Immunology
    Johns Hopkins Sidney Kimmel Cancer Center
    Baltimore, Maryland

    Consulting Agreements: Amplimmune Inc, Bristol-Myers Squibb Company, Compugen, Dendreon Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, ImmuneXcite Inc, ImmuNext Inc, Novartis Pharmaceuticals Corporation, Potenza Therapeutics, Sanofi; Patents: Amplimmune Inc, Bristol-Myers Squibb Company, Potenza Therapeutics; Stock Ownership: Compugen, ImmuneXcite Inc, ImmuNext Inc.

    David F McDermott, MD
    Associate Professor of Medicine
    Harvard Medical School
    Director, Biologic Therapy and Cutaneous Oncology Programs
    Beth Israel Deaconess Medical Center
    Leader, Kidney Cancer Program
    Dana-Farber Cancer Center
    Boston, Massachusetts

    Consulting Agreements: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Novartis Pharmaceuticals Corporation.

    Elizabeth R Plimack, MD, MS
    Director, Genitourinary Clinical Research
    Associate Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center, Temple Health
    Philadelphia, Pennsylvania

    Advisory Committee: Acceleron Pharma, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: Bristol-Myers Squibb Company, Lilly, Pfizer Inc; Contracted Research: Acceleron Pharma, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, GlaxoSmithKline, Lilly, Merck, Pfizer Inc.

    Thomas Powles, MBBS, MRCP, MD
    Professor of Urology Oncology
    Director of St Bartholomew’s Cancer Centre
    Queen Mary University of London
    London, United Kingdom

    Advisory Committee: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Roche Laboratories Inc.

    Susan F Slovin, MD, PhD
    Attending Physician, Member
    Genitourinary Oncology Service
    Sidney Kimmel Center for Prostate and Urologic Cancers
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill-Cornell Medical College
    New York, New York

    Advisory Committee: Bayer HealthCare Pharmaceuticals.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Dendreon Pharmaceuticals Inc and Genentech BioOncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

Acknowledge and close

View video: